SCHEMBL22787156

SCHEMBL22787156

COC(=O)CCCOc1ncc(C(C)=O)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.44
▸ MAPT P10636 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ PDE3B Q13370 3/20 0.37
▸ PDE3A Q14432 3/20 0.37
▸ P2RY12 Q9H244 2/20 0.37
▸ LMNA P02545 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ TBXAS1 P24557 1/20 0.36
▸ LTB4R Q15722 1/20 0.36
▸ PDE2A O00408 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22787194 0.83 HSD17B10 (0.45) TSHRL3MBTL1ALDH1A1GAAHSD17B10
SCHEMBL22787155 0.80 L3MBTL1 (0.47) TSHRMAPTL3MBTL1HPGDALDH1A1
SCHEMBL11456703 0.75 L3MBTL1 (0.71) MAPTL3MBTL1HPGDALDH1A1SMN1; SMN2
SCHEMBL2187864 0.73 MAPT (0.43) MAPTL3MBTL1HPGDSMN1; SMN2GAA
SCHEMBL2603390 0.71 L3MBTL1 (0.74) MAPTL3MBTL1HPGDALDH1A1SMN1; SMN2
SCHEMBL28706034 0.70 GAA (0.75) TSHRMAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL28706802 0.70 GAA (0.75) TSHRMAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL28693964 0.70 GAA (0.75) TSHRMAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL7355038 0.70 KMT2A (0.65) TSHRMAPTALDH1A1KMT2AMEN1
SCHEMBL2186123 0.68 L3MBTL1 (0.49) MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220267281-A1 UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-08-25 — — US disclosed
WO-2020248065-A1 UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2020-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267281-A1 UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF AADAC, ACSL3, ACSL1 TSHR 4504/4885MAPT 4186/4885L3MBTL1 4500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback